DRW3 GER Week ended 24 Jul 2026

Weekly Investor Report

Drägerwerk AG & Co. KGaA · Healthcare · Medical Devices

Open interactive chart View report data
Latest close 96.80 EUR
10.0% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 11.8% above the Trend Line and sits at 99.8% of its 52-week range. The latest completed week returned 10.0%, after a 16.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is inexpensive relative to peers. The latest news-sentiment score is 50/100. Near-term considerations: price is close to its 52-week high.

Setup score 64 out of 100
Latest Close 96.80 EUR 24 Jul 2026
1W Return 10.0% latest completed week
4W Return 16.2% short-term follow-through
12W Return 10.5% quarterly tape
Trend Breadth 90.4% 47 of 52 weeks active
Volume Ratio 1.6x vs 13-week average
What is working
  • The trend backdrop is active with a 1-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Volume is elevated versus the 13-week average, confirming attention.
What could go wrong
  • Activity pressure is negative, which weakens the current setup.
  • Next-week expectancy is negative at 42.43% based on similar historical setup states.
  • 11 reversal markers appear in the recent smart-money tape.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 10.0% Latest completed week; four-week move 16.2%. Indicator stack 53/42 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 42.43% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 50/100 5 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 11.8% above the Trend Line and sits at 99.8% of its 52-week range. The latest completed week returned 10.0%, after a 16.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.6x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5712-week average 0.71

12-week confirmation

Trend active10/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.57Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers1111 reversal markers

No recent accumulation markers. 11 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 16.2% over four weeks, 10.5% over 12 weeks, and 43.9% over one year. The current trend has remained active for 1 consecutive weeks.

Performance by holding period

1W10.0%
4W16.2%
12W10.5%
26W14.4%
52W43.9%
Active trend streak1 weeks
Active weeks in one year47
Trend breadth90.4%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.61Latest activity-pressure read.
Pressure change36.2%Four-week change in activity pressure.
Leadership19.77Latest relative-leadership reading.
RS change190.9%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is inexpensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 94% Model confidence 90%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength95/100Blend of value, momentum, and quality. Underlying universe rank 6; rank 1 is best.
Value86/100Relative valuation strength. Underlying universe rank 15; rank 1 is best.
Quality59/100Profitability and accounting quality. Underlying universe rank 42; rank 1 is best.
Momentum79/100Medium-term price momentum. Underlying universe rank 22; rank 1 is best.
Growth68/100Revenue and earnings growth. Underlying universe rank 33; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework73/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
15.8x
Price divided by trailing earnings.
Price / sales
0.5x
Market value relative to trailing revenue.
EV / EBITDA
8.6x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
7.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
45.4%
Gross profit retained from each unit of revenue.
Operating margin
5.7%
Operating profit retained from revenue.
Free-cash-flow margin
4.0%
Free cash flow generated from revenue.
Return on invested capital
9.0%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
3.3%
Latest one-year revenue growth.
EPS growth
12.1%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
52.3%
Latest one-year free-cash-flow growth.
Piotroski F-score
9/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
2.3%
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
2.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 5 relevant articles.

0 positive · 5 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-0.1%Distance below the 52-week high.
13-week volatility5.6%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+13.8%Week of 22 May.
Worst week-7.9%Week of 24 Apr.
Latest week+10.0%Week of 24 Jul.

Shape of recent returns

Strong gains8
Modest gains3
Flat weeks0
Modest losses12
Sharp losses3
Recent vol5.6%13-week weekly-return volatility.
Base vol5.4%52-week weekly-return volatility.
Up/down split22/29Count of positive and negative weeks in the 52-week window.
Average skew5.4% / -2.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape58/100

Trend, activity pressure, participation, and risk combine to a 58/100 tape read.

 Indicator analysis50/100

Latest 12-week confirmation: trend 10/12, activity pressure 0/12, relative leadership 12/12.

Activity pressure 0.57; 11 reversal markers Next-Week ExpectancyNegative 42.43%

Next-week expectancy is negative with a 42.43% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors79/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 42; Small Cap Core rank 31 SVQF73/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 103.0 of 373 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment50/100

Weighted news tone is neutral across 5 relevant articles.

Drägerwerk shares near pre-Covid high after detailed results Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202696.80 EUR10.0%86.61 EUR58.29 EUR-0.6119.77105.3KOn
17 Jul 202688.00 EUR5.0%85.62 EUR57.94 EUR-1.0110.7792.1KOff
10 Jul 202683.80 EUR-2.4%84.87 EUR57.64 EUR-1.164.9576.7KOff
3 Jul 202685.90 EUR3.1%84.26 EUR57.37 EUR-1.114.9835.9KOn
26 Jun 202683.30 EUR-1.2%83.61 EUR57.08 EUR-0.966.8041.5KOn
19 Jun 202684.30 EUR-3.9%83.12 EUR56.80 EUR-0.807.1416.2KOn
12 Jun 202687.70 EUR-3.8%82.53 EUR56.51 EUR-0.5313.428.7KOn
5 Jun 202691.20 EUR-0.7%81.84 EUR56.22 EUR-0.5617.865.1KOn
29 May 202691.80 EUR-0.5%80.99 EUR55.89 EUR-0.5017.5974.2KOn
22 May 202692.30 EUR13.8%80.30 EUR55.56 EUR-0.4819.95101.0KOn
15 May 202681.10 EUR-7.3%79.71 EUR55.23 EUR-0.5210.2587.5KOn
8 May 202687.53 EUR-0.1%79.48 EUR54.99 EUR-0.0717.67102.0KOn
1 May 202687.63 EUR-1.7%78.70 EUR54.70 EUR0.1818.8584.2KOn
24 Apr 202689.19 EUR-7.9%77.91 EUR54.42 EUR0.4022.6891.7KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.